Autopsy report · NCT00059644
Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
Cause of deathNo reason given
Life of this trial
- Registered 1 year 9 months after it had already started.
- Ran for about 2 years 11 months before it stopped.
- 560 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Tanabe Pharma Corporation
- Sponsor type
- Industry
- Conditions
- Peripheral Vascular Disease
- Interventions
- Ecraprost in lipid emulsion
- Participants
- 560
- Sites
- 27
- Countries
- United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.